579 results about "Homeostasis" patented technology

The invention relates to an application of a stable silicic acid aqueous solution in preparation of a product for treating acne, and the mass concentration of the stable silicic acid aqueous solution is 0.5-2%. The product taking the stable silicic acid aqueous solution as an active ingredient can be used for treating acne or preventing and / or treating sebaceous gland homeostasis imbalance, can fade the color of sebaceous gland spots at the mass concentration of 0.5-2%, and has an anti-acne effect, and meanwhile, the stable silicic acid aqueous solution is low in raw material cost, environment-friendly, safe and suitable for industrial production. The tretinoin can be used as a traditional tretinoin substitute medicine with a good curative effect.

The invention provides a compound with a structure as shown in a formula (I). The compound can be used as a polyphenol organic ligand to be self-assembled with metal ions to form metal polyphenol nanoparticles. The nano-particles have a bone targeting effect, are safe, effective, stable and uniform, can realize whole-body transfer, can be degraded in a bone pathology microenvironment, have regulation and control effects on bone resorption and bone formation, can cooperatively regulate and control bone balance, and have a great application prospect in the field of bone diseases such as osteoporosis. # imgabs0 #

The invention discloses a plant extract-based bisphenol-free acidic color fixing agent and a preparation method thereof, the color fixing agent adopts natural plant polyphenol as a raw material, the use of bisphenol compounds as a raw material is avoided, and bisphenol substances may induce an oxidative stress system of a human body, disturb an endocrine system and an immune system or cause in-vivo balance disorder, so that the color fixing agent has a good color fixing effect. Even the risk of increasing diabetes and heart disease is caused, and even certain reproductive toxicity is caused. The plant polyphenol compound used for preparing the color fixing agent is non-toxic and harmless, and no toxic substance is left in the color fixing agent finished product. The water-soaking-resistant color fastness and the soaping-resistant color fastness of the bisphenol-free acidic color fixing agent can be both improved to level 3 or above.

The invention relates to human hepatocyte organoids. In particular, hepatocyte organoids with modified genes involved in lipid homeostasis. The invention also relates to the use of such organoids for modelling diseases involving steatosis. Also included is the use of such organoids as models of fatty liver, such as caused by genetic as well as diet related fatty liver disorders and their use in discovery of novel drugs for treating fatty liver and related disorders. The invention further relates to agents for reducing steatosis in subjects having similar modifications as the hepatocyte organoids of the invention. The invention also relates to methods of reducing or preventing steatosis, treating or preventing cardiovascular disease; treating or preventing NAFLD, and preventing and / or reducing the risk of NASH and / or cirrhosis by increasing FADS2 activity in a subject. Also included is a FADS2 agonist, such as a small molecule, nucleic acid or polypeptide for use in said methods.

The invention provides an application of puerarin in treatment of periodontitis. The molecular mechanism of puerarin (Pue) for treating periodontitis (PDS) is verified through a plurality of in-vitro and in-vivo experimental studies. In PDS mice, Pue treatment relieves periapical tissue inflammation and bone destruction, and promotes osteogenic differentiation and autophagy of periapical tissues. In a PDS cell model, Pue treatment promotes osteogenic differentiation and mitochondrial autophagy, inhibits inflammation, maintains mitochondrial membrane potential and mitochondrial dynamic homeostasis, and activates mitochondrial Mfn2. In addition, the mitochondrial autophagy inhibitor eliminates the influence of Pue on a PDS cell model, and Mfn2 silence reverses mitochondrial autophagy enhancement induced by Pue. In-vivo tests verify that Mfn2 knockout counteracts the therapeutic effect of Pue on PDS mice. The invention provides a sufficient basis and an exact molecular mechanism for application of puerarin in treatment of periodontitis.

The invention belongs to the technical field of food functional ingredient nutriology research, and discloses application of narirutin in improving the intestinal flora homeostasis of food allergy organisms. The narirutin can adjust the relative abundance value of certain intestinal flora by adjusting the diversity of the intestinal flora of a food allergy body, improve the relative abundance of beneficial bacteria and harmful bacteria, and can influence the metabolism of short-chain fatty acid of the intestinal flora of the food allergy body, so that the food allergy body is improved. Further, the application of the narirutin in improving the intestinal flora homeostasis of food allergy organisms is realized. The application of narirutin in the research fields of nutriology, biology and pharmacology is expanded.

The invention discloses a triggering probiotic-drug conjugate and a preparation method and application thereof, and belongs to the technical field of oral drug delivery systems, the triggering probiotic-drug conjugate comprises probiotics, an adhesive inner layer formed by coordination of tannic acid and Fe < 3 + >, and an outer layer formed by pterostilbene-phospholipid bridged by ROS-responsive thioether bonds and cholesterol; the inner layer coats the surfaces of the probiotics through coordination, and the outer layer coats the outer part of the inner layer through self-assembly. An outer lipid layer is decomposed under high-concentration ROS in an inflammation colon area, and probiotics coated with pterostilbene and a tannic acid layer are released. Pterostilbene relieves inflammation and rebuilds a pathological microenvironment, and catechol groups in a tannic acid layer and the surface of the intestinal tract generate multiple interactions to promote planting of probiotics. In UC mouse models, the conjugates exhibit enhanced therapeutic effects by inhibiting inflammation, restoring intestinal barrier function, and improving intestinal microbiota homeostasis. The invention has important transformation potential in clinical application of gastrointestinal diseases.

The invention belongs to the technical field of probiotic products, and particularly relates to lactobacillus rhamnosus JM039 as well as a composition and application thereof. The preservation number of the lactobacillus rhamnosus JM039 is GDMCC No: 64409. The lactobacillus rhamnosus JM039 is a lactobacillus rhamnosus strain. The composition is prepared from lactobacillus reuteri J1, lactobacillus gasseri JM1, lactobacillus paracasei JY062, lactobacillus paracasei with the preservation number of GDMCC.No.62990, lactobacillus plantarum JY039 and lactobacillus rhamnosus JM039, and is prepared from lactobacillus reuteri J1, lactobacillus gasseri JM1, lactobacillus paracasei JY062, lactobacillus paracasei with the preservation number of GDMCC.No.62990, lactobacillus plantarum The combined bacteria of the six probiotics can improve the levels of anti-inflammatory factors and intestinal epithelium tight junction proteins and reduce the levels of proinflammatory factors and claudin-2 mRNA, so that the intestinal microenvironment homeostasis and intestinal barrier integrity are maintained through double regulation of inflammatory factors and tight junction proteins, and necrotizing enterocolitis can be relieved.

The invention discloses a BRIX1 inhibitor and application of the BRIX1 inhibitor in tumor resistance, and particularly discloses a nucleoprotein BRIX1 which is a key regulatory factor of a steady state between ribosome biogenesis and p53 activation. Research results show that inhibition of BRIX1 can induce nucleolus stress to activate p53, so that growth of tumors is inhibited. Besides, the engineered exosome is constructed, the surface of the engineered exosome is decorated with iRGD, and the engineered exosome is loaded with siRNA with BRIX1 specificity and is used for treating cancers.

The invention provides a traditional Chinese medicine monomer composition for preventing and / or treating pulmonary fibrosis as well as a preparation and application thereof, and belongs to the technical field of biological medicines. The traditional Chinese medicine monomer composition comprises the following components: schisandrin B and platycodin D. The traditional Chinese medicine monomer composition can obviously reduce fiber cell and collagen deposition, relieve inflammatory cell infiltration, obviously reduce the lung coefficient, alveolar inflammation score and pulmonary fibrosis score, and recover the normal physiological structure of rat lung tissue. The traditional Chinese medicine monomer composition provided by the invention can reduce the expression contents of KL-6, MMP-7, SP-A and SP-D and lung tissue HYP in serum, and has the effects of relieving collagen deposition and alveolar epithelium injury, maintaining alveolar homeostasis and improving pulmonary fibrosis. Therefore, the traditional Chinese medicine composition provided by the invention is definite and reliable in curative effect and can be used for preparing medicines for preventing and / or treating pulmonary fibrosis.

The invention discloses combined lactobacillus salivarius CCFM1398 for regulating and controlling bone homeostasis and relieving bone resorption and a metagen of the combined lactobacillus salivarius CCFM1398, and belongs to the technical field of microorganisms. The combined lactobacillus salivarius CCFM1398 provided by the invention is separated from oral dental plaque of healthy teenagers, has the effects of relieving bone resorption and resisting inflammation, and is specifically reflected in that expression of protein level and gene level of MC3T3-E1 cell osteoprotegerin (OPG) is improved in vitro; the bone absorption amount of orthodontic bone absorption rat alveolar bone is reduced, the number of alveolar bone osteoclasts is reduced, and the level of rat serum OPG is improved; the secretion of inflammatory factors TNF-alpha, IL-6 and MPO of the orthodontic bone absorption rat is reduced; and the pathological condition of orthodontic bone absorption rat alveolar bone tissue is improved. Therefore, the combined lactobacillus salivarius has a huge application prospect in products for relieving bone resorption and assisting in inhibiting periodontal tissue inflammation.

The invention discloses application of a bifidobacterium animalis subspecies F1-3-2 in preparation of a medicine for preventing or treating sarcopenia, belongs to the technical field of microorganism application, and provides application of the bifidobacterium animalis subspecies F1-3-2 in preparation of the medicine for preventing or treating sarcopenia. The invention relates to an application of bifidobacterium animalis subspecies F1-3-2 in preparation of a medicine for correcting intestinal flora imbalance caused by sarcopenia. The invention finds that the bifidobacterium animalis subspecies F1-3-2 can effectively improve the skeletal muscle quality of mice with sarcopenia, improve the condition of tension reduction, improve the level of serum markers in sarcopenia, regulate the homeostasis of intestinal flora so as to relieve muscular atrophy, prepare freeze-dried bacterial powder and enrich products for improving sarcopenia.

The invention discloses a composition for regulating sleep rhythm homeostasis as well as a preparation method and application thereof. The composition for regulating the sleep rhythm homeostasis is prepared from the following components in percentage by weight: 5 to 18 percent of polydextrose, 9 to 15 percent of galactooligosaccharide, 1 to 10 percent of inulin, 0.4 to 2 percent of gamma-aminobutyric acid, 0.8 to 2.2 percent of L-theanine, 0.1 to 3.5 percent of magnesium citrate, 2 to 21 percent of semen ziziphi spinosae extract, 1 to 10 percent of poria cocos extract, 0.5 to 2 percent of pericarpium citri reticulatae extract, 0.3 to 1 percent of liquorice root extract and 15 to 40 percent of maltodextrin. 5-18% of coconut oil powder MCTs, and 0.5-2% of a lily extract. According to the application, a magnesium MCTs shell-core structure is delivered by maltodextrin to form a mitochondrial piezoelectric engine so as to improve prebiotics, promote flora metabolism efficiency and energy supply feedback, activate intestinal pheochromophilic cells and improve SLC6A4 gene expression so as to improve synthesis of 5-hydroxytryptamine in the brain and activate GABA energy neurons; meanwhile, through the spina date seed and poria cocos quantum dots and a pericarpium citri reticulatae and liquorice pi-pi stacking network, the blood-brain barrier penetration rate is greatly increased, and hypothalamic CRH release is adjusted.

The growth factor profile, connective tissue matrix constituents, and immunoprivileged status of urodele extracellular matrix (ECM) and accompanying cutaneous tissue, plus the presence of antimicrobial peptides there, render urodele-derived tissue an ideal source for biological scaffolds for xenotransplantation. In particular, a biological scaffold biomaterial can be obtained by a process that entails (A) obtaining a tissue sample from a urodele, where the tissue comprises ECM, inclusive of the basement membrane, and (B) subjecting the tissue sample to a decellularization process that maintains the structural and functional integrity of the extracellular matrix, by virtue of retaining its fibrous and on-fibrous proteins, glycoaminoglycans (GAGs) and proteoglycans, while removing sufficient cellular components of the sample to reduce or eliminate antigenicity and immunogenicity for xenograft purposes. The resultant urodele-derived biomaterial can be used to enhance restoration of skin homeostasis, to reduce the severity, durations and associated damage caused by post-surgical inflammation, and to promote progression of natural healing and regeneration processes. In addition, the biomaterial promotes the formation of remodeled tissue that is comparable in quality, function, and compliance to undamaged human tissue.

A method for constructing a model for assessing the phenotypic state of a receiver and a phenotypic state model, a method for constructing a model for assessing the elastic homeostasis of a receiver and an elastic homeostasis model, a method for assessing the health state of a receiver, a method for assessing the elastic homeostasis of a receiver, a method for assessing the risk of a receiver suffering from a metabolic disease, a method for assessing whether a therapy for treating a metabolic disease of a receiver is effective, a method and system for assessing whether a metabolic health intervention solution of a receiver is effective, and a kit. The method for constructing a model for assessing the phenotypic state of a receiver comprises: selecting a plurality of markers that are involved in or affect a total of four categories of metabolism, that is, glycometabolism, lipid metabolism, amino acid metabolism and metabolic stress; selecting one to several categories as coordinate axes for establishing a model; collecting samples of n healthy receivers and samples of m receivers who are in an impaired-health or sub-healthy condition; measuring the levels of markers related to the selected coordinate axes in each sample; training a machine learning model by using the levels of the markers; and performing screening to obtain a target marker, and calculating a weight coefficient of the target marker, so as to establish the model for assessing the phenotypic state of the receiver.

The invention provides a method for verifying the protective effect of a semen descurainiae water extract on myocardial injury, so as to evaluate the pharmacodynamic effect of the semen descurainiae water extract on heart failure induced by three inducements of acute ischemia-reperfusion injury, pathological cell hypertrophy and chronic hypoxia. The method comprises the following steps: respectively constructing a hiPSC-CMs-based myocardial acute ischemia reperfusion injury model, a pathological fat myocardial injury model and a chronic hypoxic myocardial injury model, and after the myocardial injury models are established, adding a descurainia seed aqueous extract and a positive control drug for intervention. And detecting corresponding indexes to verify the effect of the descurainia seed water extract on three types of heart failure. The result shows that the semen descurainiae water extract can generate a treatment effect on myocardial injury caused by chronic hypoxia by regulating and controlling the steady state of energy metabolism, inhibiting oxidative stress cascade reaction and other mechanisms.

The invention relates to an intracerebral phosphorus homeostasis accelerant and application thereof. Specifically, a gene compensation therapy for targeting glial cells, especially astrocytes, is developed on the basis of a molecular cytology mechanism of the intracerebral phosphorus homeostasis, and can be used for repairing the intracerebral phosphorus homeostasis imbalance condition, so that the occurrence of calcification is inhibited, or the further progress of intracerebral calcification is inhibited, and the intracerebral phosphorus homeostasis is inhibited. And clinical nervous system symptoms of related patients are improved.

The invention discloses a noninvasive nerve regulation and control method and system for treating tinnitus through multi-sensory steady-state stimulation. The regulation and control method comprises the steps that tinnitus characteristics of a patient are evaluated, relevant tinnitus characteristic parameters of the patient are obtained, and a tinnitus characteristic parameter file of the patient is formed; an individualized steady-state rhythm stimulation scheme is formulated; individualized composite gamma wave band rhythm signals are generated, multiple steady-state rhythm stimulation of light, sound and electricity is applied at the same time, tinnitus responsible brain area nerve electrical activity is noninvasively adjusted through multi-mode sense organs of vision, hearing and somatosensory, and abnormal brain electrical activity is regulated and controlled in combination with real-time brain electrical feedback so as to treat tinnitus. According to the regulation and control method, the corresponding stimulation scheme is formulated based on the tinnitus characteristics of the patient, the individualized composite rhythm signals are adopted, multi-mode non-invasive stimulation such as light and sound is applied at the same time, the tinnitus responsible brain area nerve electrical activity is regulated, and the treatment effect is achieved.

Engineered food to promote health and maintain homeostasis in a subject and methods of producing the food.

The invention belongs to the technical field of biological medicine, and relates to application of a clerodendranthus spicatus tea bag in regulating intestinal excretion and reducing uric acid. One of the purposes of the invention is to provide the application of the clerodendranthus spicatus teabag in regulating intestinal tracts to reduce uric acid According to a preferred embodiment, the clerodendranthus spicatus teabag regulates ATP binding cassette transporter G2 and inhibits uricase activity. The invention provides the application of the clerodendranthus spicatus teabag in regulating the intestinal microbial environment and reducing uric acid, and the clerodendranthus spicatus teabag has remarkable beneficial effects. The clerodendranthus spicatus teabag can effectively regulate the structure and the function of intestinal microflora, especially the enrichment amount of characteristic bacteria Muriaculum in the intestinal tract, further strengthens the probiotic activity of the intestinal flora, and is helpful for maintaining the steady state of uric acid in the body. The multi-way synergistic effect not only provides an innovative strategy for preventing and treating hyperuricemia and related metabolic diseases, but also avoids side effects possibly brought by traditional medicines, and shows good application prospects and clinical values.

The invention discloses a preparation method and application of a multifunctional layered nanosheet. The biomimetic hydrogel is prepared through a hydrothermal method, folic acid (FA) is modified on the surface of the biomimetic hydrogel, and the biomimetic hydrogel has the capacity of targeted recognition of pro-inflammatory phenotype macrophages, has the biomimetic activity of multiple enzymes such as superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) and can effectively remove ROS; meanwhile, a succinate dehydrogenase (SDH) inhibitor dimethylmalonic acid (DMM) is loaded in an intercalation mode of the nano material, SDH activity is inhibited in a slow release mode, ROS outbreak caused by mitochondrial reverse electron transfer (RET) is blocked from the source, then a mitochondrial autophagy pathway mediated by BNIP3-LC3B is started, and dynamic and steady state recovery of mitochondria is achieved. The system finally realizes macrophage mitochondrial function reconstruction, oxidation environment improvement and transfer of healthy mitochondria to osteoblasts, so that the osteogenic differentiation capability is recovered, and the effect of treating osteoporosis is achieved.

The invention belongs to the field of neurobiology and drug research and development, and discloses application of NR3A as a protein target in screening or preparing drugs for preventing and / or treating depression-like behaviors. According to the invention, the expression of NR3A in hippocampus is enhanced by stereotactic injection of adeno-associated virus containing Grin3a gene. A chronic constraint stress (CRS) is adopted to induce a depressive mouse, and a sucrose preference test (SPT), a forced swimming test (FST) and an open field test (OFT) are adopted for identification. The expression of proteins such as NR3A, calpain 2 (Calpain2), neuron nitric oxide synthase (nNOS), 3-nitrotyrosine (3-NT), an NLRP3 inflammation complex and the like is detected by WesternBlot; and performing DHE staining to detect reactive oxygen species (ROS). By enhancing hippocampus NR3A expression, depression-like behaviors induced by CRS can be improved, signal cascade activated by calcium is inhibited, ROS generation and 3-NT expression are reduced, and neuroinflammation driven by NLRP3 inflammasomes is inhibited. The NR3A participates in depression-like behaviors induced by CRS, and the mechanism of the NR3A is related to calcium homeostasis regulation, ROS generation and inflammatory response driven by NLRP3 inflammasomes.

The application provides application of a TT2-SCT1 / SCT2-WR2 regulation channel in plant heat stress tolerance. The application first discloses a new signal channel involved in plant heat tolerance: a TT2-SCT1 / SCT2-WR2 signal channel; wherein, TT2 is a negative regulation factor for regulating the heat tolerance of plants or protecting (maintaining) the yield of plants in Gramineae under high temperature, SCT1 / SCT2 are also negative regulation factors for regulating the heat tolerance of plants or protecting (maintaining) the yield of plants in Gramineae under high temperature, and WR2 is a positive regulation factor for playing a role, which is beneficial to maintaining the homeostasis in plants. The application has important theoretical significance for genetic improvement of plant traits.

The invention relates to the technical field of genetic engineering, and discloses an engineering bacterium for high-yield production of D-pantothenic acid based on sugar uptake regulation and a preparation method of the engineering bacterium. The method comprises the following steps: firstly, stabilizing an RNAP promoter open complex formed on an rRNA (Ribonucleic Acid) gene by intensively expressing a necessary global regulation transcription factor CarD of mycobacterium neoaurum; secondly, performing enhanced expression on mycobacterium neoaurum Rpf / Sps family protein RpfB which serves as a resuscitation promoting factor to play a role and catalyze peptidoglycan synthesis to accelerate cell wall growth; meanwhile, the inactivated cell wall lipoprotein Lpp accumulates the outer membrane vesicles; in addition, lipoprotein NlpI responsible for adjusting the activity of endopeptidase MopS and PBP4 is deleted, and the super vesicles are generated; in addition, the mutant membrane lipid asymmetric pathway protein MlaE disturbs the homeostasis of the outer membrane and increases the formation of vesicles; in addition, the membrane anchoring protein TolA is destroyed to improve the membrane permeability; and finally, the escherichia coli gene engineering strain with greatly improved D-pantothenic acid production performance is obtained.

The invention relates to the technical field of probiotics and application thereof, in particular to a plant lactobacillus ZKAW02 strain, a fungicide and application of the fungicide. The invention relates to a plant lactobacillus ZKAW02 strain, which is classified and named as plant lactobacillus, the plant lactobacillus ZKAW02 strain is preserved in Guangdong Province Microbial Culture Collection Center on September 27, 2024, and the preservation number is GDMCC No: 65219. The invention further discloses a preparation method of the plant lactobacillus ZKAW02 strain. The plant lactobacillus ZKAW02 strain has the advantages that the plant lactobacillus ZKAW02 strain is named as plant lactobacillus, and the plant lactobacillus ZKAW02 strain is preserved in Guangdong Province Microbial Culture Collection Center on September 27, 2024. The lactobacillus plantarum ZKAW02 has the effects of remarkably reducing the cholesterol level, remarkably regulating the blood fat level of the liver and excrement and remarkably increasing the short-chain fatty acid level in the excrement of a high-fat rat, so that the expression level of lipid metabolism related signal channel genes is regulated, the intestinal flora homeostasis is regulated, the liver tissue damage is repaired, and the anti-tumor effect is achieved. The effects of regulating lipid metabolism and intestinal health are achieved.

The invention discloses application of an Hspa5 inhibitor in preparation of a medicine for preventing or treating anxiety disorder. An anxiety mouse model is constructed through chronic constraint stress (CRS), and in combination with medial amygdala kernel (MeA) transcriptome sequencing and qPCR verification, it is found that the endoplasmic reticulum molecular chaperone Hspa5 is remarkably up-regulated in the anxiety state. Furthermore, an Hspa5 specific inhibitor HA15 is locally injected into a MeA brain region, so that the anxiety-like behavior induced by the CRS is remarkably improved, and the exploration time of an open field experiment central region, the exploration time of an open arm of an elevated cross labyrinth and the exploration time of a bright box of a bright-dark box experiment are prolonged. The invention discloses the function of Hspa5 as a novel anti-anxiety target for the first time, and provides a direct experimental basis and a transformation direction for developing a novel anti-anxiety drug which is non-monoamine and targets an endoplasmic reticulum homeostasis.

The present invention provides an agent capable of modulating variable splicing in the intron of the SLC20A2 gene, and its use for modulating the expression of functional PiT2 protein to prevent and / or treat disease. The invention further provides a brain calcification model based on variable splicing in the intron of the human SLC20A2 gene, a preparation method of the brain calcification model, and application of the model to indication and analysis of the incidence stage of brain calcification, or to a model for researching phosphorus homeostasis imbalance in brain or a target of brain calcification, or to screening of drugs.

The invention discloses a composite bone graft material based on bletilla striata polysaccharide and autologous tooth bone meal as well as a preparation method and application of the composite bone graft material. The preparation method comprises the following steps: preparing bletilla striata polysaccharide, namely BSP, from bletilla striata; the method comprises the following steps: pretreating extracted teeth, and crushing to obtain autologous tooth bone powder, namely AutoBT; dissolving the BSP in water, and uniformly stirring to obtain a BSP solution; the AutoBT is poured into the BSP solution, and after standing and stirring, an AutoBT solution loaded with BSP is obtained; and carrying out vacuum drying on the AutoBT solution loaded with the BSP, and carrying out ultraviolet sterilization to obtain the composite bone graft material. The material can be applied to repairing of oral cavity bone defects, bletilla striata polysaccharide has the effects of resisting inflammation, inhibiting bacteria, promoting osteogenesis and inhibiting osteoclast, the bone steady state unbalance state in the periodontitis environment is effectively reversed, meanwhile, autologous tooth bone powder accelerates bone tissue regeneration and integration by means of the natural bionic structure and high porosity of the autologous tooth bone powder, and the bone tissue regeneration effect is improved. The risks of postoperative infection and immunological rejection are reduced.